The National Cancer Institute Inflammation and Cancer Think Tank in Cancer Biology ([NCI, 2008](#bib37){ref-type="other"}) has recognised that epidemiological and clinical research corroborates an increased risk of certain cancers in the setting of chronic inflammation. Indeed, chronic inflammation, because of both infectious and non-infectious etiologies, has been associated with an increased risk of cancer development at a number of organ sites, with infectious agents estimated to be responsible for the development of 18% of all new cancer cases worldwide ([Osburn *et al*, 2007](#bib38){ref-type="other"}). Infectious agents linked to cancer include hepatitis B virus and liver cancer, *Helicobacter pylori* and stomach cancer, and liver fluke infection and cholangiocarcinoma ([Osburn *et al*, 2007](#bib38){ref-type="other"}). In addition, a number of inflammatory conditions without an infectious aetiology result in a significantly increased cancer risk as exemplified by chronic gastroesophageal reflux-induced oesophageal cancer, proliferative inflammatory atrophy-induced prostate cancer and chronic ulcerative colitis-associated colorectal cancer ([Schottenfeld and Beebe-Dimmer, 2006](#bib46){ref-type="other"}; [Osburn *et al*, 2007](#bib38){ref-type="other"}). Activation of inflammatory cells is accompanied by an increase in the release of reactive oxygen species (ROS) at the site of inflammation. Excess levels of ROS, due to chronic inflammation, may contribute to carcinogenesis by reacting with DNA to form oxidative DNA adducts possibly leading to mutagenesis and impaired regulation of cellular growth ([Osburn *et al*, 2007](#bib38){ref-type="other"}). Many of the processes involved in inflammation (e.g., leukocyte migration, dilatation of local vasculature with increased permeability and blood flow and angiogenesis), when found in association with tumours, are more likely to contribute to tumour growth, progression and metastasis than to elicit an effective host antitumour response ([NCI, 2008](#bib37){ref-type="other"}). Recently, it has been shown ([Dougan and Dranoff, 2008](#bib10){ref-type="other"}) that signals downstream of the receptor for advanced glycation end products can fuel chronic inflammation, creating a microenvironment that is ideal for tumour formation in a mouse model of skin cancer.

Nuclear factor E2-related factor 2 (Nrf2 or Nfe2l2) is indispensable to cellular defense against many chemical insults of endogenous and exogenous origin, which play major roles in the etiopathogenesis of many cancers and inflammation-related diseases such as inflammatory bowel disease and Parkinson\'s disease ([Nair *et al*, 2007a](#bib34){ref-type="other"}). Under basal conditions, Nrf2 -- a member of the Cap-N-Collar family of transcription factors -- is sequestered in the cytoplasm by Keap1 resulting in enhanced proteasomal degradation of Nrf2. In conditions of oxidative stress, Nrf2 is released from Keap1 either by direct oxidative modification of Keap1 or after phosphorylation by redox-sensitive protein kinases, translocates to the nucleus and, in combination with other transcription factors, activates transcription of genes containing an antioxidant response element (ARE) in their promoter regions resulting in a cytoprotective adaptive response. This adaptive response is characterised by upregulation of a battery of antioxidative enzymes and decreased sensitivity to oxidative damage and cytotoxicity. These antioxidative enzymes have also been shown to attenuate inflammatory damage and neutralise ROS implicated in inflammatory signalling pathways. We have also reported ([Khor *et al*, 2006](#bib20){ref-type="other"}) that Nrf2 could play an important role in protecting intestinal integrity, through the regulation of pro-inflammatory cytokines and induction of phase II detoxifying enzymes. Besides, we have demonstrated ([Yuan *et al*, 2006](#bib60){ref-type="other"}) that mitogen-activated protein kinase (MAPK) pathways such as extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK) signalling pathways played important and positive roles in chemopreventive agent butylated hydroxyanisole-induced and Nrf2-dependent regulation of ARE-mediated gene expression, as well as the nuclear translocation of Nrf2 in HepG2 cells. We have observed earlier ([Yu *et al*, 2000](#bib59){ref-type="other"}) that the activation of MAPK pathways induces ARE-mediated gene expression through a Nrf2-dependent mechanism. In addition, we have also shown ([Shen *et al*, 2004](#bib49){ref-type="other"}) that different segments of the Nrf2 transactivation domain have different transactivation potentials and that different MAPKs have differential effects on Nrf2 transcriptional activity, with ERK and JNK pathways playing an unequivocal role in the positive regulation of Nrf2 transactivation domain activity ([Shen *et al*, 2004](#bib49){ref-type="other"}; [Nair *et al*, 2007a](#bib34){ref-type="other"}).

Importantly, recent mouse studies provide strong and direct genetic evidence that the classical IKK-*β* (inhibitor of nuclear factor-*κ*B (NF-*κ*B) kinase-*β*)-dependent NF-*κ*B activation pathway, which was proposed several years ago to be the molecular link between inflammation and carcinogenesis, is a crucial mediator of tumour promotion ([Karin and Greten, 2005](#bib17){ref-type="other"}). Indeed, several pro-inflammatory cytokines and chemokines -- such as tumour necrosis factor (TNF), IL-1, IL-6 and CXC-chemokine ligand 8 (CXCL8; also known as IL-8), all of which are encoded by the target genes of the IKK-*β*-dependent NF-*κ*B activation pathway -- are associated with tumour development and progression in humans and mice. It has, thus, been hypothesised that activation of NF-*κ*B by the classical IKK-dependent pathway is a crucial mediator of inflammation-induced tumour growth and progression, as well as an important modulator of tumour surveillance and rejection ([Karin and Greten, 2005](#bib17){ref-type="other"}). We have also demonstrated ([Xu *et al*, 2005](#bib57){ref-type="other"}) that the suppression of NF-*κ*B and NF-*κ*B-regulated gene expression (VEGF, cyclin D1 and Bcl-XL) by chemopreventive isothiocyanates sulphoraphane and phenethyl isothiocyanate (PEITC) is mainly mediated through the inhibition of IKK phosphorylation, particularly IKK-*β*, and the inhibition of I*κ*B-*α* phosphorylation and degradation, as well as the decrease of nuclear translocation of p65 in human prostate cancer PC-3 cells. Recently, it has been observed ([Murakami *et al*, 2007](#bib32){ref-type="other"}) that PEITC suppresses receptor activator of NF-*κ*B ligand-induced osteoclastogenesis by blocking the activation of ERK1/2 and p38 MAPK in RAW264.7 macrophages. Besides, HL60 cells treated with fisetin presented high expression of NF-*κ*B, activation of p38 MAPK and an increase of phosphoprotein levels ([de Sousa *et al*, 2007](#bib8){ref-type="other"}).

Pro-inflammatory biomarkers such as IL-1*β*, IL-6, TNF-*α*, inducible nitric oxide synthase and cycloxygenase-2, which are all effector genes regulated by the NF-*κ*B pathway, have been noted ([Li *et al*, 2008](#bib25){ref-type="other"}) to exhibit greater induction in Nrf2-deficient mice as compared with wild-type mice, indicating that ablation of Nrf2 seems to accelerate NF-*κ*B-mediated pro-inflammatory reactions. Besides, it has been shown recently ([Liu *et al*, 2008](#bib27){ref-type="other"}) that NF-*κ*B competes with Nrf2 for binding to transcriptional coactivator CREB-binding protein and also promotes the recruitment of the corepressor histone deacetylase 3 to MafK leading to local histone hypoacetylation, thus, serving as a negative regulator of Nrf2--ARE signalling. Further, as constitutively active NF-*κ*B occurs in many inflammatory and tumour tissues ([Liu *et al*, 2008](#bib27){ref-type="other"}), and as Nrf2 is implicated in the etiopathogenesis of many cancers and inflammation-associated conditions ([Nair *et al*, 2007a](#bib34){ref-type="other"}), we elected to select these two important transcriptional regulators in this study to explore the potential for putative crosstalk between Nrf2 and NF-*κ*B signalling pathways in inflammation/injury and carcinogenesis. We performed *in silico* bioinformatic analyses to delineate conserved transcription factor-binding sites (TFBSs) or regulatory motifs in the promoter regions of human and murine Nrf2 and Nfkb1, as well as coregulated genes. We performed multiple sequence alignment of Nrf2 and Nfkb1 genes in five mammalian species and studied conserved biological features. We also looked at microarray data from public repositories such as Oncomine ([Rhodes *et al*, 2005](#bib45){ref-type="other"}), Gene Expression Omnibus (GEO), Public Expression Profiling Resource (PEPR), as well as data sets from the Kong Laboratory, to dissect the role(s) of key regulatory genes in these selected inflammation/cancer signatures and constructed a regulatory network for concerted modulation of Nrf2 and Nfkb1 involving several members of the MAPK family. Our *in silico* analyses show that concerted modulation of Nrf2 and NF-*κ*B signalling pathways, and putative crosstalk involving multiple members of the MAPK family, may be potential molecular events governing inflammation and carcinogenesis.

Materials and methods
=====================

Identification of microarray data sets bearing inflammation/injury or cancer signatures
---------------------------------------------------------------------------------------

We perused several microarray data sets from public repositories such as Oncomine, GEO, PEPR, as well as data sets from the Kong Laboratory ([Nair *et al*, 2006](#bib36){ref-type="other"}, [2007b](#bib35){ref-type="other"}, [2008](#bib33){ref-type="other"}). We selected 13 data sets that presented distinct signatures of inflammation or injury or carcinogenesis. Specifically, these studies reflected data on prostate cancer, spinal trauma, inflammatory response to injury and genes modulated by chemopreventive agents/toxicants in Nrf2-deficient animal models. These studies encompassed three mammalian species -- human, mouse and rat -- and exhibited modulation of both Nrf2 (Nfe2l2) and Nfkb1 genes as well as coregulated genes.

Promoter analyses for transcription factor-binding sites
--------------------------------------------------------

The promoter analyses were performed in the Cai Laboratory using Genomatix MatInspector ([Quandt *et al*, 1995](#bib43){ref-type="other"}; [Cartharius *et al*, 2005](#bib4){ref-type="other"}). Briefly, human promoter sequences of NFE2L2 and NFKB1, or corresponding murine promoter sequences, were retrieved from Gene2Promoter (Genomatix). Comparative promoter analyses were then performed by input of these sequences in FASTA format into MatInspector using optimised default matrix similarity thresholds. The similar and/or functionally related TFBSs were grouped into 'matrix families,\' and graphical representations of common TFBS were generated. The 'V\$\' prefixes to the individual matrices are representative of the Vertebrate MatInspector matrix library. Similarly, we also elucidated common TFBS among the three topmost conserved human regulatory sequences after multiple alignment (as described below) of NRF2 and NFKB1 sequences.

Multiple species alignment of Nrf2 (Nfe2l2) and Nfkb1 sequences
---------------------------------------------------------------

Non-coding sequences of Nfe2l2 and Nfkb1 genes in five mammalian species -- human, chimpanzee, dog, mouse and rat -- were retrieved using the Non-Coding Sequence Retrieval System (NCSRS) for comparative genomic analysis of gene regulatory elements that has been previously developed and published ([Doh *et al*, 2007](#bib9){ref-type="other"}) by the Cai Laboratory, and is readily available at <http://cell.rutgers.edu/ncsrs/>. Multiple sequence alignment was performed by submitting the non-coding sequences to MLAGAN (Multi-LAGAN, Multi-Limited Area Global Alignment of Nucleotides) ([Brudno *et al*, 2003](#bib3){ref-type="other"}), which is compatible with the VISTA visualisation tool. The MLAGAN alignments were, thus, visualised using VISTA by projecting them to pairwise alignments with respect to one reference sequence (human) as baseline. The common TFBSs between Nfe2l2 and Nfkb1 between the top biological features that were conserved in multiple species were then determined using Genomatix MatInspector as described earlier in Materials and Methods under Promoter Analyses for TFBS.

Construction and validation of canonical first-generation regulatory network involving Nrf2 (Nfe2l2) and Nfkb1
--------------------------------------------------------------------------------------------------------------

A putative regulatory network for Nrf2 (Nfe2l2) and Nfkb1, representing 59 nodes and 253 potential interactions, was constructed using Cytoscape 2.5.2 software ([Shannon *et al*, 2003](#bib47){ref-type="other"}). Further, we validated our network using PubGene ([Jenssen *et al*, 2001](#bib15){ref-type="other"}), a literature network where connections are strong indicators of biological interaction. Additional validation was achieved by the generation of a biological network with these gene identifiers through the use of Ingenuity Pathways Analysis (Ingenuity Systems®; [www.ingenuity.com](http://www.ingenuity.com)). For this purpose, a data set containing gene identifiers was uploaded into the application. Each gene identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base. These genes, called focus genes, were overlaid onto a global molecular network developed from information contained in the Ingenuity Pathways Knowledge Base. Networks of these focus genes were then algorithmically generated based on their connectivity. In addition, we used dChip application ([Li and Hung Wong, 2001](#bib22){ref-type="other"}; [Li and Wong, 2001](#bib23){ref-type="other"}) to assess differential expression of MAPKs in cancer *vs* developmental or non-cancerous tissue/cell lines. Briefly, the CEL files created from each data set were first imported into dChip software for further data characterisation. A gene information file with current annotations and functional gene ontology was generated and the Affymetrix Chip Description File (CDF) was specified. The data were then normalised in dChip, and the expression value for each gene was determined by calculating the average of differences in intensity (perfect match intensity minus mismatch intensity) between its probe pairs. Finally, clustering and enrichment analysis was performed.

A putative model for Nrf2--Nfkb1 interactions in inflammation and carcinogenesis
--------------------------------------------------------------------------------

A pictorial model for Nrf2--Nfkb1 interactions was generated using Pathway Builder Tool 2.0 available from Protein Lounge, San Diego, CA, USA.

Results
=======

Identification of microarray data sets bearing inflammation/injury or cancer signatures
---------------------------------------------------------------------------------------

To investigate distinct signatures of inflammation/injury or carcinogenesis, we perused several microarray data sets from public repositories such as Oncomine, GEO, PEPR, as well as microarray data sets from the Kong Laboratory. As summarised in [Table 1](#tbl1){ref-type="table"}, we selected 13 data sets that presented distinct signatures of inflammation/injury or carcinogenesis. Specifically, these studies reflected data on prostate cancer, spinal trauma, inflammatory response to injury and genes modulated by chemopreventive agents/toxicants in Nrf2-deficient animal models. These studies encompassed three mammalian species -- human, mouse and rat -- and exhibited modulation of both Nrf2 (or Nrf2-dependent) and Nfkb1 genes as well as coregulated genes. In other words, all these studies presented modulation of both Nrf2 (Nfe2l2) and Nfkb1 genes in concert, except for the studies with Nrf2-deficient animal models where Nrf2-dependent genes were elucidated. Interestingly, these data sets exhibited modulation of several key members of the MAPK family as well as cofactors of Nrf2 and Nfkb1. This literature pre-screen encouraged us to investigate further the regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis using an *in silico* bioinformatic approach.

Comparative promoter analyses of Nrf2 (Nfe2l2) and Nfkb1 for conserved transcription factor-binding sites
---------------------------------------------------------------------------------------------------------

To identify conserved TFBS signatures, we performed comparative analyses of Nrf2 and Nfkb1 murine promoter sequences ([Figure 1A](#fig1){ref-type="fig"}) using Genomatix MatInspector ([Quandt *et al*, 1995](#bib43){ref-type="other"}; [Cartharius *et al*, 2005](#bib4){ref-type="other"}) as described in Materials and Methods. We also studied NRF2 and NFKB1 human promoter sequences ([Figure 1B](#fig1){ref-type="fig"}) similarly. [Table 2](#tbl2){ref-type="table"} includes, as indicated, an alphabetical listing of the conserved vertebrate (V\$) matrix families between these two transcription factors. The major human matrix families included activator protein 4 and related proteins, Ccaat/enhancer-binding protein, Camp-responsive element-binding proteins, E2F-myc activator/cell cycle regulator, E-box-binding factors, basic and erythroid krueppel-like factors, fork head domain factors, Myc-associated zinc fingers, nuclear receptor subfamily 2 factors, p53 tumour suppressor, RXR heterodimer-binding sites, SOX/SRY-sex/testis-determining and related HMG box factors, signal transducer and activator of transcription (STAT), X-box-binding factors, Zinc-binding protein factors and two-handed zinc finger homoeodomain transcription factors, among others. Some key conserved murine matrix families included AHR-arnt heterodimers and AHR-related factors, activator protein 2, activator protein 4 and related proteins, E2F-myc activator/cell cycle regulator, E-box-binding factors, basic and erythroid krueppel-like factors, farnesoid X-activated receptor response elements, heat-shock factors, Ikaros zinc finger family, Myc-associated zinc fingers, NF-*κ*B/c-rel, nuclear receptor subfamily 2 factors, nuclear respiratory factor 1, p53 tumour suppressor, pleomorphic adenoma gene, RXR heterodimer-binding sites, SOX/SRY-sex/testis-determining and related HMG box factors, serum response element-binding factor, Tata-binding protein factor, zinc-binding protein factors, among others. Indeed, as evident from [Table 2](#tbl2){ref-type="table"}, several matrix families were conserved between Nrf2 and Nfkb1 in both human and murine promoters.

Multiple species alignment of Nrf2 (Nfe2l2) and Nfkb1 sequences
---------------------------------------------------------------

With the objective of investigating conserved biological features across different mammalian species, we performed multiple species alignment of Nrf2 (Nfe2l2) and Nfkb1 sequences as described in Materials and Methods. We used NCSRS for comparative genomic analysis of gene regulatory elements that has been previously developed and published ([Doh *et al*, 2007](#bib9){ref-type="other"}), and is readily available at <http://cell.rutgers.edu/ncsrs/> and retrieved non-coding sequences of Nfe2l2 and Nfkb1 genes in five mammalian species -- human, chimpanzee, dog, mouse and rat. As shown in [Figures 2A and B](#fig2){ref-type="fig"}, we performed multiple sequence alignment using MLAGAN ([Brudno *et al*, 2003](#bib3){ref-type="other"}) for Nfe2l2 and Nfkb1 genes, respectively, with respect to one reference sequence (human) as baseline. The phylogenetic tree for Nfe2l2 and Nfkb1 in the five species under consideration was constructed ([Figure 2C](#fig2){ref-type="fig"}). The conserved biological features across species for each of Nfe2l2 and Nfkb1 genes were perused, and the top five features for Nfe2l2 and the top three features for Nfkb1, as numbered in [Figures 2A and B](#fig2){ref-type="fig"}, are listed in [Tables 3A and B](#tbl3){ref-type="table"}, respectively. Sequence 4 for Nfe2l2 and sequence 1 for Nfkb1 exhibited the highest degree of conservation across species at 98.86 and 86.58%, respectively. In addition, the top three conserved sequences in the human sequences of both these genes (sequences 4, 3 and 2 for Nfe2l2 in that order and sequences 1, 2 and 3 for Nfkb1 in that order) as evident from [Tables 3A and B](#tbl3){ref-type="table"} were submitted to Genomatix MatInspector. The common TFBSs between Nfe2l2 and Nfkb1 between these biological features that were conserved in multiple species were then determined ([Figure 2D](#fig2){ref-type="fig"}) and tabulated along with the other TFBS results for comparative promoter analyses in [Table 2](#tbl2){ref-type="table"} discussed earlier.

Construction and validation of a canonical first-generation regulatory network involving Nrf2 (Nfe2l2) and Nfkb1
----------------------------------------------------------------------------------------------------------------

To construct a canonical first-generation biological network for Nrf2--Nfkb1 interactions, we streamlined our study to five data sets summarised in [Table 4](#tbl4){ref-type="table"}, which were representative of the most distinct inflammation/injury and cancer signatures from the 13 data sets perused earlier. We obtained gene expression values for 59 genes, as shown in [Table 4](#tbl4){ref-type="table"}, including Nrf2 (Nfe2l2), Nfkb1, several cofactors and many members of the MAPK family from these data sets. As shown in [Figure 3A](#fig3){ref-type="fig"}, we constructed a putative first-generation regulatory network for Nrf2 (Nfe2l2) and Nfkb1, representing 59 nodes and 253 potential interactions using Cytoscape 2.5.2 software ([Shannon *et al*, 2003](#bib47){ref-type="other"}). Further, we validated our network by submitting 20 representative genes from [Table 4](#tbl4){ref-type="table"} to PubGene ([Jenssen *et al*, 2001](#bib15){ref-type="other"}), a literature network where connections are strong indicators of biological interaction, and retrieved biological networks in human ([Figure 3B](#fig3){ref-type="fig"}) and mouse ([Figure 3C](#fig3){ref-type="fig"}), thus delineating gene signatures that validated the putative biological role(s) of the genes elucidated in this *in silico* study that served as the source and target nodes in our regulatory network. We further validated our network by querying Ingenuity Pathways Analysis (Ingenuity Systems; [www.ingenuity.com](http://www.ingenuity.com)) application with the 59 gene identifiers forming the basis of our network and obtained a biological network ([Figure 3D](#fig3){ref-type="fig"}) with a high degree of functional crosstalk based on the Ingenuity Knowledge Base reiterating the potential for crosstalk between multiple members of the MAPK family that might modulate the Nrf2--Nfkb1 interactions as indicated in our canonical network ([Figure 3A](#fig3){ref-type="fig"}). Furthermore, we used dChip application ([Li and Hung Wong, 2001](#bib22){ref-type="other"}; [Li and Wong, 2001](#bib23){ref-type="other"}) to assess the differential expression of MAPKs in cancerous *vs* developmental or non-cancerous tissue/cell lines by using several unrelated microarray data sets from the GEO resource at the NCBI including GSM116104--116106: bronchial smooth muscle cells; GSM133871-133873: retinal pigment epithelial cell line; GSM156176--156178: skeletal muscle; GSM187371--187373: untreated LNCaP cells; GSM211446--211448: normal adrenal gland; GSM286756--286758: untreated MCF7 cells; GSM74875--74880: benign prostate tissue; GSM74881--74887: clinically localised primary prostate cancer; and GSM74888--74893: metastatic prostate cancer. Results from this analysis ([Figure 3E](#fig3){ref-type="fig"}) show the differential expression of several MAPKs in cancer *vs* non-cancerous tissue.

A putative model for Nrf2--Nfkb1 interactions in inflammation and carcinogenesis
--------------------------------------------------------------------------------

On the basis of the extensive experience ([Yu *et al*, 2000](#bib59){ref-type="other"}; [Li *et al*, 2005](#bib24){ref-type="other"}, [2006](#bib26){ref-type="other"}; [Yuan *et al*, 2006](#bib60){ref-type="other"}; [Nair *et al*, 2007a](#bib34){ref-type="other"}; [Prawan *et al*, 2008](#bib40){ref-type="other"}) of the Kong Laboratory with Nrf2--Keap1 pathway and role(s) of MAPK/dietary chemopreventives/toxicants, our many microarray studies ([Shen *et al*, 2005](#bib51){ref-type="other"}, [2006](#bib50){ref-type="other"}; [Keum *et al*, 2006](#bib19){ref-type="other"}; [Nair *et al*, 2006](#bib36){ref-type="other"}, [2007b](#bib35){ref-type="other"}, [2008](#bib33){ref-type="other"}; [Hu *et al*, 2006a](#bib12){ref-type="other"}, [2006b](#bib13){ref-type="other"}; [Barve *et al*, 2008](#bib2){ref-type="other"}) in Nrf2-deficient mice, our studies ([Jeong *et al*, 2004](#bib16){ref-type="other"}; [Xu *et al*, 2005](#bib57){ref-type="other"}) on NF-*κ*B pathway and chemopreventive agents, and the gene signatures elicited in inflammation and carcinogenesis in this *in silico* study using our data as well as publicly available data from other research groups as indicated earlier, we generated a pictorial model ([Figure 4](#fig4){ref-type="fig"}) for Nrf2--Nfkb1 interactions using Pathway Builder Tool 2.0. available from Protein Lounge, San Diego, CA. In essence, chemical signals generated by dietary chemopreventive agents or toxicants, or inflammatory signals, may cause Nrf2 nuclear translocation that sets in motion a dynamic machinery of coactivators and corepressors that may form a multi-molecular complex with Nrf2 to modulate transcriptional response through the ARE. Inflammation may also cause release of NF-*κ*b1 from I*κ*B and stimulate NF-*κ*b1 nuclear translocation to modulate transcriptional response through the NF-*κ*b1 response element, NF-*κ*b-RE, along with cofactors of NF-*κ*b1. Several members of the MAPK family may act in concert with Nrf2 and Nfkb1 with multiple interactions between the members of the putative complex to elicit the chemopreventive and pharmacotoxicological events in inflammation and carcinogenesis.

Discussion
==========

[Karin and Greten (2005)](#bib17){ref-type="other"} succinctly noted that carcinogenesis may be divided into three mechanistic phases: initiation (which involves stable genomic alterations), promotion (which involves the proliferation of genetically altered cells) and progression (which involves an increase in the size of the tumour, the spreading of the tumour and the acquisition of additional genetic changes). In 1863, Rudolf Virchow observed leukocytes in neoplastic tissues and suggested ([Balkwill and Mantovani, 2001](#bib1){ref-type="other"}) that the 'lymphoreticular infiltrate\' reflected the origin of cancer at sites of chronic inflammation. Besides, persistent and recurrent episodes of inflammation ([McCulloch *et al*, 2006](#bib29){ref-type="other"}), mediated by aberrant activation of innate and acquired immunity, characterise a wide spectrum of idiopathic and infectious chronic inflammatory disorders. In response to tissue injury ([Coussens and Werb, 2002](#bib7){ref-type="other"}), a multifactorial network of chemical signals initiate and maintain a host response designed to 'heal\' the afflicted tissue involving activation and directed migration of leukocytes (neutrophils, monocytes and eosinophils) from the venous system to sites of damage, and tissue mast cells also play a significant role. Interestingly, inflammation and innate immunity most commonly exert pro-tumorigenic effects ([Karin and Greten, 2005](#bib17){ref-type="other"}) mediated through different types of leukocytes, including normal tissue macrophages, tumour-associated macrophages, dendritic cells, neutrophils, mast cells and T cells, which are recruited to the tumour microenvironment through interactions with local stromal cells and malignant cells. These leukocytes produce cytokines, and growth and angiogenic factors, as well as matrix-degrading proteases (such as the matrix metalloproteinases MMP1, MMP3 and MMP9) and their inhibitors, which allow tumour cells to proliferate, invade and metastasise ([Karin and Greten, 2005](#bib17){ref-type="other"}). Although the causal relationship between inflammation, innate immunity and cancer is more widely accepted, many of the molecular and cellular mechanisms mediating this relationship remain unresolved ([Coussens and Werb, 2002](#bib7){ref-type="other"}). Many studies have implicated Nrf2 (Nfe2l2) in cancer ([Ramos-Gomez *et al*, 2001](#bib44){ref-type="other"}; [Katsuoka *et al*, 2005](#bib18){ref-type="other"}; [Sporn and Liby, 2005](#bib52){ref-type="other"}; [Nair *et al*, 2007a](#bib34){ref-type="other"}; [Pearson *et al*, 2008](#bib39){ref-type="other"}) or inflammation-associated diseases such as colitis ([Khor *et al*, 2006](#bib20){ref-type="other"}; [Osburn *et al*, 2007](#bib38){ref-type="other"}), and Parkinson\'s disease ([Clements *et al*, 2006](#bib6){ref-type="other"}), and NF-*κ*B in inflammation ([Muller-Ladner *et al*, 2002](#bib31){ref-type="other"}; [Profita *et al*, 2008](#bib41){ref-type="other"}; [Puthia *et al*, 2008](#bib42){ref-type="other"}) and cancer ([Xu *et al*, 2005](#bib57){ref-type="other"}; [Cilloni *et al*, 2006](#bib5){ref-type="other"}; [Sun and Zhang, 2007](#bib54){ref-type="other"}; [McDonnell *et al*, 2008](#bib30){ref-type="other"}). Indeed, the identification of combinatorial, or synergistic, transcription factors and the elucidation of relationships among them are of great importance for understanding transcriptional regulation as well as transcription factor networks ([Hu *et al*, 2007](#bib14){ref-type="other"}). However, despite a growing recognition of the important role(s) played by these two pivotal transcription factors, the regulatory potential for crosstalk between these two important transcription factors in inflammation and carcinogenesis has not been explored.

The perusal of several microarray data sets from public repositories such as Oncomine, GEO, PEPR, as well as data sets from the Kong Laboratory, facilitated the identification of 13 data sets ([Table 1](#tbl1){ref-type="table"}) presenting distinct signatures of inflammation/injury or carcinogenesis that served as our literature pre-screen for concerted modulation of Nrf2 and Nfkb1 genes. The comparative analyses of TFBS in these two gene promoters revealed that many matrix families were conserved between human NRF2 and NFKB1 promoters, and between murine Nrf2 and Nfkb1 promoter regions ([Figure 1](#fig1){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Furthermore, as elucidated in [Table 2](#tbl2){ref-type="table"}, several functionally important matrix families were also found to be common across human and murine species, including activator protein 4, E2F-myc activator/cell cycle regulators (V\$E2FF), E-box-binding factors, basic and erythroid krueppel-like factors, p53 tumour suppressor and RXR heterodimer-binding sites (V\$RXRF), among others. The identification of V\$E2FF is significant because disruption of retinoblastoma protein, a key controller of E2F activity and G1/S transition in the cell cycle, can alter the growth-inhibitory potential of TGF-*β* in the inflammatory milieu of chronic liver disease and contribute to cancer development ([Sheahan *et al*, 2007](#bib48){ref-type="other"}). Inflammatory conditions can enhance the genotoxic effects of carcinogenic polycyclic aromatic hydrocarbons such as benzo\[a\]pyrene (BaP) through the upregulation of CYP1B1 expression associated with increased phosphorylation of p53 tumour suppressor at Ser-15 residue, enhanced accumulation of cells in the S-phase of the cell cycle and potentiation of BaP-induced apoptosis ([Umannova *et al*, 2008](#bib56){ref-type="other"}). Thus, the presence of conserved p53 TFBS in Nrf2/Nfkb1 promoters may point to a critical role for inflammation in the etiopathogenesis of cancer and underscore the relevance of crosstalk between these two transcription factors. The identification of V\$RXRF is important as RXR physically interacts with peroxisome proliferator-activated receptor (PPAR-*α*), a major player in lipid metabolism and inflammation, and PPAR-*α* agonists such as fenofibrate inhibit NF-*κ*B DNA-binding activity ([Xu *et al*, 2006](#bib58){ref-type="other"}). In addition, a conserved TFBS for NF-*κ*B itself ([Table 2](#tbl2){ref-type="table"}) was found to be present in murine promoter regions of Nrf2 and Nfkb1, strengthening the potential for crosstalk between these two transcription factors. Our multiple sequence alignments ([Figures 2A and B](#fig2){ref-type="fig"} and [Tables 3A and B](#tbl3){ref-type="table"}) enabled the study of conserved biological features for each gene across five mammalian species and the construction of a phylogenetic tree ([Figure 2C](#fig2){ref-type="fig"}). Interestingly, several key biological features were elicited on subjecting the top three conserved human sequences of each gene to comparative promoter analyses ([Figure 2D](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). Notably, autoimmune regulatory element-binding factors (V\$AIRE) and PPAR (or V\$PERO) were conserved in these promoters. Recently, a cyclopentenonic prostaglandin 15-deoxy-delta(12,14)-prostaglandin J(2) has been shown to inhibit TNF-related apoptosis-inducing ligand mRNA expression by downregulating the activity of its promoter in T lymphocytes, with NF-*κ*B being identified as a direct target of this prostanoid that is also regulated by the activation of PPAR-*γ* ([Fionda *et al*, 2007](#bib11){ref-type="other"}). The identification of PPAR in the promoter regions of Nrf2 and Nfkb1 in this study, thus, reinforces the significance of these transcription factors and provides a possible mechanistic pathway for crosstalk in inflammation and cancer. Interestingly, a recent study ([Kim *et al*, 2008](#bib21){ref-type="other"}) has reported that treatment of human brain astrocytes with double-stranded RNA induced interferon regulatory factor 3 (IRF3) phosphorylation and nuclear translocation followed by activation of STAT1 along with a concomitant activation of NF-*κ*B and MAPK cascade members (p38, JNK and ERK). In this study, we identified interferon regulatory factors (IRFF) and STAT as being conserved in Nrf2 and Nfkb1 promoters, as well as MAPK members in our regulatory network ([Figure 3A](#fig3){ref-type="fig"}), which agrees with the mechanistic evidence from the brain astrocyte study. It has been observed ([Tliba *et al*, 2006](#bib55){ref-type="other"}) that stimulation with pro-inflammatory cytokines of CD38, known to be responsible for lung airway inflammation, rendered it insensitive to treatment with glucocorticoids such as fluticasone, dexamethasone or budesonide, by inhibiting steroid-induced glucocorticoid-responsive element (GRE)-dependent gene transcription. We also identified conserved GRE in the Nrf2/Nfkb1 promoters that further validated our results as biologically relevant. In addition, cell cycle regulators, heat-shock factors and several other matrices were found to be conserved between the two genes, thus, underscoring the biological relevance, and the intrinsic complexity, of Nrf2/Nfkb1 crosstalk from a functional standpoint.

Further, we streamlined our study to five data sets ([Table 4](#tbl4){ref-type="table"}), which were representative of the most distinct inflammation/injury and cancer signatures of interest and constructed a canonical first-generation regulatory network ([Figure 3A](#fig3){ref-type="fig"}) for Nrf2 (Nfe2l2) and Nfkb1, representing 59 nodes and 253 potential interactions. We generated functionally relevant PubGene literature networks in human ([Figure 3B](#fig3){ref-type="fig"}) and mouse ([Figure 3C](#fig3){ref-type="fig"}), using the Ingenuity Knowledge Base ([Figure 3D](#fig3){ref-type="fig"}), thus delineating gene signatures that validated the biological role(s), and potential for crosstalk, of the genes elucidated in this *in silico* study. We also assessed the expression of MAPKs in several randomly picked, unrelated microarray data sets of cancerous and non-cancerous origin and showed that various MAPKs are differentially expressed in cancer *vs* developmental or non-cancerous tissue/cell lines ([Figure 3E](#fig3){ref-type="fig"}). Our future study includes the expansion of our study objectives to generate more detailed second-generation or third-generation regulatory networks for Nrf2 and Nfkb1 as more functional data emerge on these gene targets of interest and their interactions with coactivator/corepressor modules that associate with them. Interestingly, as shown in our current first-generation network ([Figure 3A](#fig3){ref-type="fig"}), several MAPKs play a central role in mediating the transcriptional effects of Nrf2 and Nfkb1. This is, indeed, in consonance with the known role of MAPKs in potentiating Nrf2-mediated ARE activation ([Yu *et al*, 2000](#bib59){ref-type="other"}; [Shen *et al*, 2004](#bib49){ref-type="other"}; [Yuan *et al*, 2006](#bib60){ref-type="other"}) and their role in modulating NF-*κ*B ([Murakami *et al*, 2007](#bib32){ref-type="other"}; [de Sousa *et al*, 2007](#bib8){ref-type="other"}), thus, further underscoring the biological applicability of our results. Finally, we present a gestalt pictorial overview ([Figure 4](#fig4){ref-type="fig"}) of our current knowledge of concerted modulation of Nrf2 and Nfkb1 based on the data from this study and our extensive experience in cancer chemoprevention.

The results from our current *in silico* study may strengthen the possibility that scientists could, in the future, consider pursuing Nrf2, Nfkb1 and MAPKs as potential targets in early drug discovery screens for the management of inflammation and cancer. In contemporary times, systems biology has interfaced with the drug discovery process to enable high-throughput screening of multiple drug targets and target-based leads. Indeed, a combination of high-throughput screening, kinase-specific libraries and structure-based drug design has facilitated the discovery of selective kinase inhibitors ([Manning and Davis, 2003](#bib28){ref-type="other"}). Needless to add, the benefits of applying molecular profiling to drug discovery and development include much lower failure rates at all stages of the drug development pipeline, faster progression from discovery through to clinical trials and more successful therapies for patient subgroups ([Stoughton and Friend, 2005](#bib53){ref-type="other"}). Thus, the development of specific inhibitors that might regulate the specific crosstalk between the two central pleiotropic transcription factors Nrf2 and Nfkb1, and with the associated family of kinases, may be one of many strategies that might aid in the drug discovery process. Taken together, our study provides a canonical framework to understand the regulatory potential for concerted modulation of Nrf2 and Nfkb1 in inflammation and cancer. Further studies addressing this question with specific emphasis on cofactor modules binding to these transcription factors and coregulation with upstream signalling molecules in the MAPK cascade will enable a better appreciation of the emerging key role(s) of, and the crosstalk between, these two transcription factors in inflammation and carcinogenesis.

This study was supported in part by RO1 CA094828 to Ah-Ng Tony Kong and CA133675 to Li Cai from the National Institutes of Health (NIH).

![(**A**) A conserved TFBS between mouse Nfe2l2 and Nfkb1. Vertebrate (V\$) matrix families conserved between murine Nfe2l2 and Nfkb1 promoter regions were identified using Genomatix MatInspector. (**B**) A conserved TFBS between human NFE2L2 and NFKB1. Vertebrate (V\$) matrix families conserved between human NFE2L2 and NFKB1 promoter regions were identified using Genomatix MatInspector.](6604703f1){#fig1}

![Multiple species alignment. Non-coding sequences of Nfe2l2 and Nfkb1 genes in five mammalian species -- human, chimpanzee, dog, mouse and rat -- were retrieved using the Non-Coding Sequence Retrieval System (NCSRS) for comparative genomic analysis of gene regulatory elements. Multiple sequence alignment was performed by submitting the non-coding sequences to MLAGAN and visualised by projecting them to pairwise alignments with respect to one reference sequence (human) as baseline. Pink regions, conserved non-coding sequences (CNS); dark blue regions, exons. The numbers indicate CNS that were identified across species. (**A)** Multiple species alignment for Nfe2l2; (**B**) multiple species alignment for Nfkb1; (**C**) phylogenetic tree for Nfe2l2 and Nfkb1; (**D**) a conserved TFBS between NFE2L2 and NFKB1 among top matching human sequences.](6604703f2){#fig2}

![A canonical regulatory network for Nrf2--Nfkb1 interactions in inflammation-associated carcinogenesis. (**A**) A putative regulatory network for Nrf2 (Nfe2l2) and Nfkb1 representing 59 nodes and 253 potential interactions implicating several members of the MAPK family; (**B**) literature network in humans; (**C**) literature network in mice; (**D**) functional crosstalk in biological network of Nfe2l2, Nfkb1 and various members of the MAPK cascade; (**E**) differential expression of MAPKs in cancer *vs* developmental or non-cancerous tissue/cell lines (GSM116104--116106: bronchial smooth muscle cells; GSM133871--133873: retinal pigment epithelial cell line; GSM156176--156178: skeletal muscle; GSM187371--187373: untreated LNCaP cells; GSM211446--211448: normal adrenal gland; GSM286756--286758: untreated MCF7 cells; GSM74875--74880: benign prostate tissue; GSM74881--74887: clinically localised primary prostate cancer; GSM74888--74893: metastatic prostate cancer).](6604703f3){#fig3}

![A putative model for Nrf2---Nfkb1 interactions in inflammation and carcinogenesis. Chemical signals generated by dietary chemopreventive agents or toxicants, or inflammatory signals, may cause Nrf2 nuclear translocation that sets in motion a dynamic machinery of coactivators and corepressors that may form a multimolecular complex with Nrf2 for modulating transcriptional response through the antioxidant response element, ARE. Inflammation may also cause release of NF-*κ*B from I*κ*B and stimulate NF-*κ*B nuclear translocation to modulate transcriptional response through the NF-*κ*B response element, NF-*κ*B-RE, along with the cofactors of NF-*κ*B. Several members of the MAPK family may act in concert with Nrf2 and Nfkb1 with multiple interactions between the members of the putative complex to elicit the chemopreventive and pharmacotoxicological events in inflammation and carcinogenesis.](6604703f4){#fig4}

###### 

Microarray data sets bearing inflammation/injury or cancer signatures

  **Species**   **Tissue**                  **Study**     **Data source**   **Descriptor**                                     **Affymetrix platform**
  ------------- --------------------------- ------------- ----------------- -------------------------------------------------- -------------------------
  Human         Prostate                    Lapointe      Oncomine          Prostate cancer                                    Non-Affymetrix
  Human         Prostate                    Luo           Oncomine          Prostate cancer and benign prostatic hyperplasia   Non-Affymetrix
  Mouse         Lung                        Kleeberger    GEO               Hyperoxic lung injury                              MG U74Av2
  Mouse         Lung                        Papaiahgari   GEO               Lung injury and inflammatory response              MG 430A 2.0
  Mouse         Spleen and liver            Li            GEO               Autoimmune disease and Nrf2                        MG U74Av2
  Mouse         Type II cells               Machireddy    GEO               Nrf2 wild-type and knockout cells                  MG 430 2.0
  Mouse         Prostate                    Nair 1        Kong Laboratory   EGCG+SFN combination treatment                     MG 430 2.0
  Mouse         Small intestine and liver   Nair 2        Kong Laboratory   BHA treatment                                      MG 430 2.0
  Mouse         Small intestine and liver   Nair 3        Kong Laboratory   Induction of ER stress with TM                     MG 430 2.0
  Rat           Spinal cord                 Faden 1       PEPR              Supraspinal tracts                                 RG_U34A
  Rat           Spinal cord                 Faden 2       PEPR              Trauma above T9                                    RG_U34A
  Rat           Spinal cord                 Faden 3       PEPR              Trauma below T9                                    RG_U34A
  Rat           Spinal cord                 Faden 4       PEPR              Trauma T9                                          RG_U34A

BHA=butylated hydroxyanisole; EGCG=epigallocatechin-3-gallate; ER=endoplasmic reticulum; SFN=sulphoraphane; TM=tunicamycin.

All Nair data sets are from the Kong Laboratory as discussed in Materials and Methods; all Faden data sets are as defined by descriptors detailed above at the PEPR resource; all other data sets are as defined by descriptors detailed above at the Oncomine or GEO resources.

###### 

Human and murine matrix families conserved between Nrf2 and Nfkb1

  **Matrix family (Human NRF2 *vs* NFKB1)**   **Matrix family (Murine Nrf2 *vs* Nfkb1)**   **Matrix family conserved after multiple species alignment (NRF2 *vs* NFKB1)**   **Family information**
  ------------------------------------------- -------------------------------------------- -------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  --                                          V\$AHRR                                      --                                                                               AHR-arnt heterodimers and AHR-related factors
  --                                          --                                           V\$AIRE                                                                          Autoimmune regulatory element-binding factor
  --                                          --                                           V\$AP1R                                                                          MAF- and AP1-related factors
  --                                          V\$AP2F                                      --                                                                               Activator protein 2
  V\$AP4R                                     V\$AP4R                                      --                                                                               Activator protein 4 and related proteins
  --                                          --                                           V\$ATBF                                                                          AT-binding transcription factor
  --                                          V\$BCL6                                      V\$BCL6                                                                          POZ domain zinc finger expressed in B-cells
  --                                          --                                           V\$BRAC                                                                          Brachyury gene, mesoderm developmental factor
  --                                          --                                           V\$BRNF                                                                          Brn POU domain factors
  --                                          --                                           V\$CAAT                                                                          CCAAT-binding factors
  --                                          --                                           V\$CART                                                                          Cart-1 (cartilage homoeoprotein 1)
  --                                          --                                           V\$CDXF                                                                          Vertebrate caudal related homoeodomain protein
  V\$CEBP                                     --                                           --                                                                               Ccaat/enhancer-binding protein
  V\$CHRF                                     --                                           V\$CHRF                                                                          Cell cycle regulators: cell cycle homology element
  --                                          --                                           V\$CIZF                                                                          CAS-interating zinc finger protein
  --                                          --                                           V\$CLOX                                                                          CLOX and CLOX homology (CDP) factors
  --                                          --                                           V\$COMP                                                                          Factors that cooperate with myogenic proteins
  V\$CREB                                     --                                           V\$CREB                                                                          Camp-responsive element-binding proteins
  --                                          V\$CTCF                                      --                                                                               CTCF and BORIS gene family, transcriptional regulators with 11 highly conserved zinc finger domains
  V\$E2FF                                     V\$E2FF                                      --                                                                               E2F-myc activator/cell cycle regulator
  --                                          V\$E4FF                                      --                                                                               Ubiquitous GLI-krueppel-like zinc finger involved in cell cycle regulation
  V\$EBOX                                     V\$EBOX                                      --                                                                               E-box-binding factors
  --                                          V\$EGRF                                      --                                                                               EGR/nerve growth factor-induced protein C and related factors
  V\$EKLF                                     V\$EKLF                                      V\$EKLF                                                                          Basic and erythroid krueppel-like factors
  --                                          V\$EREF                                      --                                                                               Estrogen response elements
  V\$ETSF                                     V\$ETSF                                      --                                                                               Human and murine ETS1 factors
  --                                          --                                           V\$EVI1                                                                          EVI1 myeloid-transforming protein
  V\$FKHD                                     --                                           V\$FKHD                                                                          Fork head domain factors
  --                                          V\$FXRE                                      --                                                                               Farnesoid X-activated receptor response elements
  V\$GATA                                     V\$GATA                                      V\$GATA                                                                          GATA-binding factors
  V\$GFI1                                     --                                           V\$GFI1                                                                          Growth factor independence transcriptional repressor
  --                                          --                                           V\$GREF                                                                          Glucocorticoid responsive and related elements
  --                                          --                                           V\$GRHL                                                                          Grainyhead-like transcription factors
  V\$HAND                                     --                                           --                                                                               bHLH transcription factor dimer of HAND2 and E12
  --                                          V\$HEAT                                      V\$HEAT                                                                          Heat-shock factors
  --                                          V\$HESF                                      --                                                                               Vertebrate homologues of enhancer of split complex
  --                                          --                                           V\$HNF1                                                                          Hepatic nuclear factor 1
  --                                          --                                           V\$HNF6                                                                          Onecut homoeodomain factor HNF6
  --                                          --                                           V\$HOMF                                                                          Homoeodomain transcription factors
  --                                          --                                           V\$HOXC                                                                          HOX--PBX complexes
  V\$HOXF                                     V\$HOXF                                      V\$HOXF                                                                          Factors with moderate activity to homoeodomain consensus sequence
  --                                          V\$IKRS                                      --                                                                               Ikaros zinc finger family
  --                                          --                                           V\$IRFF                                                                          Interferon regulatory factors
  V\$LEFF                                     --                                           V\$LEFF                                                                          LEF1/TCF, involved in the Wnt signal transduction pathway
  --                                          --                                           V\$LHXF                                                                          Lim homoeodomain factors
  V\$MAZF                                     V\$MAZF                                      --                                                                               Myc-associated zinc fingers
  --                                          --                                           V\$MEF2                                                                          MEF2, myocyte-specific enhancer-binding factor
  V\$MYBL                                     --                                           --                                                                               Cellular and viral myb-like transcriptional regulators
  V\$MYOD                                     V\$MYOD                                      --                                                                               Myoblast-determining factors
  --                                          --                                           V\$MYT1                                                                          MYT1 C2HC zinc finger protein
  --                                          V\$MZF1                                      --                                                                               Myeloid zinc finger 1 factors
  V\$NEUR                                     --                                           V\$NEUR                                                                          NeuroD, *β*2, HLH domain
  --                                          --                                           V\$NF1F                                                                          Nuclear factor 1
  --                                          --                                           V\$NFAT                                                                          Nuclear factor of activated T cells
  --                                          V\$NFKB                                      --                                                                               Nuclear factor *κ* B/c-rel
  --                                          --                                           V\$NKX6                                                                          NK6 homoeobox transcription factors
  --                                          --                                           V\$NKXH                                                                          NKX homoeodomain factors
  V\$NR2F                                     V\$NR2F                                      V\$NR2F                                                                          Nuclear receptor subfamily 2 factors
  --                                          V\$NRF1                                      --                                                                               Nuclear respiratory factor 1
  --                                          --                                           V\$OCT1                                                                          Octamer-binding protein
  --                                          --                                           V\$OCTP                                                                          OCT1-binding factor (POU-specific domain)
  V\$P53F                                     V\$P53F                                      --                                                                               p53 tumour suppressor
  --                                          --                                           V\$PARF                                                                          PAR/bZIP family
  V\$PAX5                                     --                                           --                                                                               PAX-5 B cell-specific activator protein
  --                                          V\$PAX6                                      V\$PAX6                                                                          PAX-4/PAX-6 paired domain-binding sites
  --                                          --                                           V\$PBXC                                                                          PBX1--MEIS1 complexes
  --                                          --                                           V\$PDX1                                                                          Pancreatic and intestinal homoeodomain transcription factor
  --                                          --                                           V\$PERO                                                                          Peroxisome proliferator-activated receptor
  --                                          --                                           V\$PIT1                                                                          GHF-1 pituitary-specific pou domain transcription factor
  --                                          V\$PLAG                                      --                                                                               Pleomorphic adenoma gene
  V\$PLZF                                     --                                           V\$PLZF                                                                          C2H2 zinc finger protein PLZF
  --                                          --                                           V\$PRDF                                                                          Positive regulatory domain I-binding factor
  --                                          --                                           V\$PTF1                                                                          Pancreas transcription factor 1, heterotrimeric transcription factor
  --                                          --                                           V\$RBIT                                                                          Regulator of B-cell IgH transcription
  --                                          --                                           V\$RUSH                                                                          SWI/SNF-related nucleophosphoproteins with a RING finger DNA-binding motif
  V\$RXRF                                     V\$RXRF                                      V\$RXRF                                                                          RXR heterodimer-binding sites
  --                                          --                                           V\$SATB                                                                          Special AT-rich sequence-binding protein
  V\$SF1F                                     --                                           V\$SF1F                                                                          Vertebrate steroidogenic factor
  --                                          V\$SMAD                                      --                                                                               Vertebrate SMAD family of transcription factors
  --                                          --                                           V\$SNAP                                                                          snRNA-activating protein complex
  V\$SORY                                     V\$SORY                                      V\$SORY                                                                          SOX/SRY-sex/testis-determining and related HMG box factors
  V\$SP1F                                     V\$SP1F                                      V\$SP1F                                                                          GC-Box factors SP1/GC
  --                                          V\$SRFF                                      V\$SRFF                                                                          Serum response element-binding factor
  V\$STAT                                     --                                           V\$STAT                                                                          Signal transducer and activator of transcription
  --                                          --                                           V\$TALE                                                                          TALE homoeodomain class-recognising TG motifs
  --                                          V\$TBPF                                      V\$TBPF                                                                          Tata-binding protein factor
  --                                          V\$WHNF                                      --                                                                               Winged helix-binding sites
  V\$XBBF                                     --                                           --                                                                               X-box-binding factors
  V\$ZBPF                                     V\$ZBPF                                      --                                                                               Zinc-binding protein factors
  V\$ZF35                                     --                                           --                                                                               Zinc finger protein ZNF35
  V\$ZFHX                                     --                                           V\$ZFHX                                                                          Two-handed zinc finger homoeodomain transcription factors

###### 

\(A\) Multiple species alignment for Nfe2l2. (B) Multiple species alignment for Nfkb1

  **Nfe2l2**       **CNS start**   **CNS end**   **% id**   **Location**   **Length**   **Score**   **Chr**   **Strand**   **Start**   **End**
  ------------ --- --------------- ------------- ---------- -------------- ------------ ----------- --------- ------------ ----------- -----------
  **(A)**                                                                                                                              
               1                                 84.2                      200.50       87.57                                           
  Human            4424            4568          --         Intergenic     144                      2         −            177796698   177796842
  Chimpanzee       1559            12467         98.4       Intergenic                              2b        −            182248910   182259818
  Dog              4037            4426          78.9       Intergenic     389                      36        −            24010936    24011325
  Mouse            3993            4131          79.6       Intergenic     138                      2         −            75470119    75470257
  Rat              4002            4133          80.0       Intergenic     131                      3         −            58360804    58360935
               2                                 79.9                      801.25       93.25                                           
  Human            46618           47576         --         Intronic       958                      2         −            177838892   177839850
  Chimpanzee       16433           72741         98.0       Intronic                                2b        −            182263784   182320092
  Dog              44082           45048         76.3       Intronic       966                      36        −            24050981    24051947
  Mouse            49275           49911         73.0       Intronic       636                      2         −            75515401    75516037
  Rat              48247           48892         72.3       Intronic       645                      3         −            58405049    58405694
               3                                 81.6                      746.50       94.04                                           
  Human            63951           64978         --         Intronic       1027                     2         −            177856225   177857252
  Chimpanzee       16433           72741         98.0       Intronic                                2b        −            182263784   182320092
  Dog              63914           64953         78.0       Intronic       1039                     36        −            24070813    24071852
  Mouse            69040           69553         74.9       Intronic       513                      2         −            75535166    75535679
  Rat              68447           68854         75.5       Intronic       407                      3         −            58425249    58425656
               4                                 82.8                      962.25       98.86                                           
  Human            95699           97201         --         Intronic       1502                     2         −            177887973   177889475
  Chimpanzee       93603           105622        98.3       Intronic                                2b        −            182340954   182352973
  Dog              94052           95563         80.9       Intronic       1511                     36        −            24100951    24102462
  Mouse            99967           100384        76.4       Intronic       417                      2         −            75566093    75566510
  Rat              103210          103629        75.7       Intronic       419                      3         −            58460012    58460431
               5                                 82.8                      418.75       89.74                                           
  Human            112361          112533        --         Intronic       172                      2         −            177904635   177904807
  Chimpanzee       113121          117879        98.1       Intronic                                2b        −            182360472   182365230
  Dog              105905          106887        82.1       Intronic       517                      36        −            24112804    24113786
  Mouse            115077          115617        74.8       Intronic       540                      2         −            75581203    75581743
  Rat              119448          119894        76.1       Intronic       446                      3         −            58476250    58476696
                                                                                                                                        
  **(B)**                                                                                                                              
               1                                 78                        491          86.58                                           
  Human            75272           75516         --         Intergenic     244                      4         \+           103675774   103675545
  Rat              190119          189890        77         Intergenic     229                      2         −            233663290   233663525
  Mouse            585736          585501        80         Intergenic     235                      3         −            135287512   135286504
  Dog              52140           53148         78         Intergenic     1008                     32        \+           26791395    26841008
  Chimpanzee       67709           117322        98         Intergenic     49613                    4         \+           105654198   105654198
               2                                 80                        319          84.82                                           
  Human            93740           94016         --         Intergenic     276                      4         \+           103659473   103659195
  Rat              173818          173540        79         Intergenic     278                      2         −            233651850   233652129
  Mouse            574340          574061        78         Intergenic     279                      3         −            135307030   135306630
  Dog              72266           72666         81         Intergenic     400                      32        \+           26791395    26841008
  Chimpanzee       67709           117322        98         Intergenic     49613                    4         \+           105654198   105654198
               3                                 74                        469          81.92                                           
  Human            148427          148852        --         Intergenic     425                      4         \+           103626900   103626486
  Rat              141245          140831        73         Intergenic     414                      2         −            233620618   233620924
  Mouse            543135          542829        73         Intergenic     306                      3         −            135342413   135341726
  Dog              107362          108049        76         Intergenic     687                      32        \+           26841253    26877988
  Chimpanzee       117567          154302        99         Intergenic     36735                    4         \+           105654198   105654198

Chr=chromosome; CNS=conserved non-coding sequences.

###### 

Canonical first-generation regulatory network members representing putative crosstalk between Nrf2 (Nfe2l2) and Nfkb1 in inflammation-associated carcinogenesis^a^

  **Sr. no.**   **GenBank accession no.**   **Gene name**                                                                       **Gene symbol**    **Papaiahgari lung injury and inflammation**  **SFN+EGCG Nrf2-dependent genes**    **BHA Nrf2- dependent genes**   **Tunicamycin Nrf2-dependent genes**   **Faden supraspinal tracts**
  ------------- --------------------------- ----------------------------------------------------------------------------------- ----------------- ---------------------------------------------- ----------------------------------- ------------------------------- -------------------------------------- ------------------------------
  1             NM_172154                   Ligand-dependent nuclear receptor corepressor                                       Lcor                                    --                       −3.25                                             --                                  --                                 --
  2             NM_010756                   v-maf musculoaponeurotic fibrosarcoma oncogene family, protein G (avian)            Mafg                                    --                       --                                               2.45                                 --                                 --
  3             NM_008927                   Mitogen-activated protein kinase kinase 1                                           Map2k1                                 −2.7                      −4.12                                            2.28                                 --                                1.59
  4             NM_023138                   Mitogen-activated protein kinase kinase 2                                           Map2k2                                  --                       --                                               2.75                                1.15                               1.1
  5             NM_009157                   Mitogen-activated protein kinase kinase 4                                           Map2k4                                −1.55                      −3.31                                             --                                −1.68                                --
  6             NM_011840                   Mitogen-activated protein kinase kinase 5                                           Map2k5                                −1.56                      --                                               −1.45                                --                                1.59
  7             NM_011943                   Mitogen-activated protein kinase kinase 6                                           Map2k6                                  --                       −3.98                                             --                                  --                                1.19
  8             NM_011944                   Mitogen-activated protein kinase kinase 7                                           Map2k7                                −1.32                      --                                               −0.37                              −0.16                                --
  9             NM_011945                   Mitogen-activated protein kinase kinase kinase 1                                    Map3k1                                  --                       --                                               −0.28                              −0.18                               1.11
  10            NM_011946                   Mitogen-activated protein kinase kinase kinase 2                                    Map3k2                                  --                       −5.02                                             --                                 2.25                                --
  11            NM_011947                   Mitogen-activated protein kinase kinase kinase 3                                    Map3k3                                −2.08                      --                                                --                                  --                                 --
  12            NM_011948                   Mitogen-activated protein kinase kinase kinase 4                                    Map3k4                                −1.87                      −3.52                                            −1.98                               1.51                                --
  13            NM_008580                   Mitogen-activated protein kinase kinase kinase 5                                    Map3k5                                −1.71                                                                        --                                  --                                 --
  14            NM_016693                   Mitogen-activated protein kinase kinase kinase 6                                    Map3k6                                 1.58                      −5.25                                            3.25                                 --                                 --
  15            NM_172688                   Mitogen-activated protein kinase kinase kinase 7                                    Map3k7                                 1.51                      −3.07                                            2.52                                3.29                                --
  16            NM_025609                   Mitogen-activated protein kinase kinase kinase 7-interacting protein 1              Map3k7ip1                               --                       −3.93                                             --                                −1.91                                --
  17            NM_138667                   Mitogen-activated protein kinase kinase kinase 7-interacting protein 2              Map3k7ip2                             −1.56                      **--**                                          **--**                              **--**                             **--**
  18            NM_007746                   Mitogen-activated protein kinase kinase kinase 8                                    Map3k8                                −2.04                      --                                               −0.58                               2.76                               1.55
  19            NM_177395                   Mitogen-activated protein kinase kinase kinase 9                                    Map3k9                                  --                       −6.48                                            3.06                                4.77                                --
  20            NM_009582                   Mitogen-activated protein kinase kinase kinase 12                                   Map3k12                               −7.07                      −3.51                                           **--**                              **--**                             **--**
  21            NM_016896                   Mitogen-activated protein kinase kinase kinase 14                                   Map3k14                                1.38                      --                                               2.12                                1.51                                --
  22            NM_008279                   Mitogen-activated protein kinase kinase kinase kinase 1                             Map4k1                                  --                       −3.35                                             --                                  --                                1.4
  23            NM_009006                   Mitogen-activated protein kinase kinase kinase kinase 2                             Map4k2                                −6.72                                                                       2.35                               −1.35                                --
  24            NM_001081357                Mitogen-activated protein kinase kinase kinase kinase 3                             Map4k3                                −1.73                                                                        --                                  --                                 --
  25            NM_008696                   Mitogen-activated protein kinase kinase kinase kinase 4                             Map4k4                                −1.58                      −3.54                                            2.46                                 --                               −0.74
  26            NM_201519                   Mitogen-activated protein kinase kinase kinase kinase 5                             Map4k5                                −2.45                      −3.28                                            3.94                               −2.52                                --
  27            NM_031248                   Mitogen-activated protein-binding protein-interacting protein                       Mapbpip                                2.29                                                                        --                                  --                                 --
  28            NM_001038663                Mitogen-activated protein kinase 1                                                  Mapk1                                   --                       --                                                --                                 1.08                               1.51
  29            NM_011952                   Mitogen-activated protein kinase 3                                                  Mapk3 (ERK1)                           −1.4                      −7.48                                             --                                  --                                1.09
  30            NM_172632                   Mitogen-activated protein kinase 4                                                  Mapk4                                   --                       −3.51                                             --                                  --                                1.11
  31            NM_015806                   Mitogen-activated protein kinase 6                                                  Mapk6                                   --                       −3.53                                            2.11                                1.76                               1.07
  32            NM_011841                   Mitogen-activated protein kinase 7                                                  Mapk7                                 −16.44                     --                                                --                                  --                               −0.99
  33            NM_016700                   Mitogen-activated protein kinase 8                                                  Mapk8                                   --                       --                                               10.39                              12.43                               1.21
  34            NM_011162                   Mitogen-activated protein kinase 8-interacting protein 1                            Mapk8ip1                               2.22                      −10.62                                            --                                  --                               −0.84
  35            NM_016961                   Mitogen-activated protein kinase 9                                                  Mapk9                                 −1.88                      −4.77                                            1.68                                2.33                               1.4
  36            NM_009158                   Mitogen-activated protein kinase 10                                                 Mapk10                                 1.47                      --                                               2.25                                 --                                1.29
  37            NM_011161                   Mitogen-activated protein kinase 11                                                 Mapk11                                  --                       −10.9                                            1.78                                2.32                                --
  38            NM_013871                   Mitogen-activated protein kinase 12                                                 Mapk12                                  --                       --                                               −0.24                                --                               −0.88
  39            NM_011950                   Mitogen-activated protein kinase 13                                                 Mapk13                                 1.44                      --                                                --                                −0.21                                --
  40            NM_011951                   Mitogen-activated protein kinase 14                                                 Mapk14                                −1.62                      --                                               1.14                               −0.46                               1.38
  41            NM_145527                   Mitogen-activated protein kinase-activating death domain                            Mapkadd(Madd)                           --                       1.03                                                                                                                      
  42            NM_177345                   Mitogen-activated protein kinase-associated protein 1                               Mapkap1                               −1.62                      −6.56                                            −0.34                                --                                 --
  43            NM_008551                   Mitogen-activated protein kinase-activated protein kinase 2                         Mapkapk2                                --                       --                                                --                                 4.31                               1.34
  44            NM_178907                   Mitogen-activated protein kinase-activated protein kinase 3                         Mapkapk3                                --                       −3.39                                             --                                 2.38                               1.19
  45            NM_010765                   Mitogen-activated protein kinase-activated protein kinase 5                         Mapkapk5                                --                       −4.58                                            −0.42                              −0.47                                --
  46            NM_011941                   Mitogen-activated protein kinase binding protein 1                                  Mapkbp1                                1.42                      --                                                --                                  --                                 --
  47            NM_010881                   Nuclear receptor coactivator 1                                                      Ncoa1                                   --                       −3.55                                             --                                  --                                 --
  48            NM_008679                   Nuclear receptor coactivator 3                                                      Ncoa3                                   --                       --                                               −0.12                                --                                 --
  49            NM_144892                   Nuclear receptor coactivator 5                                                      Ncoa5                                   --                       --                                                --                                14.65                                --
  50            NM_172495                   Nuclear receptor coactivator 7                                                      Ncoa7                                   --                       −4.46                                             --                                  --                                 --
  51            NM_011308                   Nuclear receptor corepressor 1                                                      Ncor1                                   --                       −5.37                                            3.39                                 --                                 --
  52            NM_008689                   Nuclear factor of kappa light chain gene enhancer in B-cells 1, p105                Nfkb1                                 −1.52                      --                                                --                                  --                                1.21
  53            NM_019408                   Nuclear factor of kappa light polypeptide gene enhancer in B cells 2, p49/p100      Nfkb2                                 −2.56                      --                                                --                                  --                                 --
  54            NM_010907                   Nuclear factor of kappa light-chain gene enhancer in B-cell inhibitor, alpha        Nfkbia                                  --                       --                                                --                                  --                               −0.77
  55            NM_030612                   Nuclear factor of kappa light polypeptide gene enhancer in B cell inhibitor, zeta   Nfkbiz                                  --                       --                                                --                                 2.67                                --
  56            NM_028024                   NFKB inhibitor-interacting Ras-like protein 2                                       Nkiras2                               −1.33                      --                                                --                                  --                               −0.94
  57            NM_010902                   Nuclear factor, erythroid-derived 2, like 2                                         Nrf2                                   1.54                      --                                                --                                  --                                1.26
  58            NM_173440                   Nuclear receptor-interacting protein 1                                              Nrip1                                   --                       --                                               2.63                                2.87                                --
  59            NM_020005                   P300/CBP-associated factor                                                          P/caf                                   --                       --                                                --                                 2.33                                --

BHA=butylated hydroxyanisole; EGCG=epigallocatechin-3-gallate; ER=endoplasmic reticulum; SFN=sulphoraphane.

Fold-change values are listed.

[^1]: Current address: Amrita School of Biotechnology and Amrita Institute of Medical Sciences and Research Centre Amrita Vishwa Vidyapeetham University, Amritapuri, Clappana P.O., Kollam-690525, Kerala, India
